Venmax Drugs & Pharmaceuticals Ltd
Venmax Drugs & Pharmaceuticals Ltd Live Price Chart
Venmax Drugs & Pharmaceuticals Ltd Technicals
| 20 Day | ₹ 25.316 |
| 50 Day | ₹ 26.118 |
| 100 Day | ₹ 26.344 |
| 200 Day | ₹ 25.047 |
| 20 Day | ₹ 25.482 |
| 50 Day | ₹ 26.687 |
| 100 Day | ₹ 26.218 |
| 200 Day | ₹ 26.618 |
Venmax Drugs & Pharmaceuticals Ltd Performance
| Previous Close | ₹ 25.47 |
| High | ₹ 28 |
| Volume | 139 |
| 52W Range | ₹ 17.51 - ₹ 36.96 |
| Open | ₹ 28 |
| Low | ₹ 22.95 |
| Market Cap | ₹ 15 Cr |
Venmax Drugs & Pharmaceuticals Ltd Fundamentals
| ROCE | 3.105 |
| P/E Ratio | 69.210 |
| P/B Ratio | 2.340 |
| Industry P/E | 2.340 |
| Debt to Equity | 39.828 |
| ROE | 4.020 |
| EPS | 0.390 |
| Dividend Yield | 0.000 |
| Book Value | 11.531 |
| Face Value | 10.000 |
Venmax Drugs & Pharmaceuticals Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 1.8605 | 0.1986 | 0.4193 | 1.983 | 0.3493107 |
| Total Expenses | 1.8746 | 0.1117 | 0.1936 | 0.1364 | 0.511109 |
| Profit After Tax | -0.0105 | 0.0645 | 0.2256 | 1.8463 | -0.1624628 |
Venmax Drugs & Pharmaceuticals Ltd Shareholding Pattern
| Promoter Holdings | 15.135 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.000 % |
| Retail | 64.252 % |
| Others - | 20.613 % |
About Venmax Drugs & Pharmaceuticals Ltd
History of Venmax Drugs & Pharmaceuticals Ltd
Venmax Drugs & Pharmaceuticals Limited, (VDPL) was initially incorporated as Private Company as 'Yenkay Medico Private Limited', on 28 September, 1998. The Company thereafter changed its name to 'Yenkey Drugs & Pharmaceuticals Private Limited' on 18 January, 1995. It became a Public Limited Company on February 3, 1995 as 'Yenkey Drugs & Pharmaceuticals Limited'. Finally, the Company changed its name to 'Venmax Drugs & Pharmaceuticals Limited' on April 13, 2009. For the past six months, Company focused on establishing chain of Medical Stores with a brand name as 'Ananya Pharma' under the Venmax Drugs & Pharma Limited, with the backing support of Formulations plant (Suzichem Labs). At present, Company is engaged in the business of pharmaceutical products, drug intermediaries & API's etc. The Company is developing the oncology products in R&D. Planning to establish a manufacturing UNIT with cGMP facility at Pharma Cluster at Hyderabad, to meet the export demand. ...
